{
    "nct_id": "NCT05458284",
    "official_title": "Acupuncture for Taxane-Induced Peripheral Neuropathy Prevention (ATP): A Phase II Randomized, Placebo Controlled Trial",
    "inclusion_criteria": "Screening Phase:\n\n* English or Spanish-proficient men and women aged ≥18 years\n* Histological diagnoses of invasive carcinoma of the breast\n* Plan to receive curative intent chemotherapy regimen containing 12 weeks weekly paclitaxel or nab-paclitaxel as standard of care\n\nIntervention Phase:\n\n* TIPN grade ≥1 based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, developed while receiving taxane\n* ≥ 4 4 weeks of either weekly paclitaxel or nab-paclitaxel, or paclitaxel or abraxane with dosing every 2-3 weeks planned, as standard of care and at treating physician's discretion\n* Willing to adhere to requirement that no new pain medication or dose changes be taken throughout the first 12 weeks of the study period\n* Willing to adhere to all study-related procedures, including randomization to one of the two possible acupuncture treatments\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Screening Phase:\n\n* Pre-existing peripheral neuropathy within 28 days of screening consent\n* Currently taking anti-neuropathy medication such as gabapentin, pregabalin, duloxetine or glutamine\n\nIntervention Phase:\n\n* Currently taking anti-neuropathy medication such as gabapentin, pregabalin, duloxetine or glutamine\n* Use of acupuncture for symptom management within 28 days of intervention consent",
    "miscellaneous_criteria": ""
}